Sven Pischke1, Patrick Behrendt, Claus-Thomas Bock, Wolfgang Jilg, Michael P Manns, Heiner Wedemeyer. 1. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hanover, German Centre for Infection Research, Hanover, TWINCORE Institute for Experimental Infection Research, Hanover, Health Care Center at the University Medical Center Hamburg-Eppendorf, Robert Koch Institute Berlin, Consiliary Laboratory for Hepatitis A and Hepatitis E, Institute for Medical Microbiology and Hygiene, University Hospital Regensburg, Regensburg.
Abstract
BACKGROUND: At least 17% of the population in Germany has been infected with the hepatitis E virus (HEV); thus, HEV infections are more frequent than was previously assumed. However, fewer than 500 HEV infections were reported to the Robert Koch Institute in 2013. METHOD: Review of pertinent literature retrieved by a selective search in PubMed. RESULTS: Persons living in Germany generally acquire hepatitis E infection within the country by consuming infected and undercooked pork; in rare cases, hepatitis E infections are imported from the tropics. HEV can be transmitted via blood products, blood transfusions, and organ transplantation. More than 99% of HEV infections are asymptomatic and self-limiting, but there are also severe cases with acute liver failure. Immunosuppressed persons can develop chronic HEV infection, potentially leading, within a few years, to liver cirrhosis with life-threatening sequelae. Moreover, HEV infection may be associated with extrahepatic manifestations such as Guillain-Barré syndrome. In two retrospectively evaluated case series, ribavirin was found to be active against HEV and can be used to treat either acute or chronic HEV infection. CONCLUSION: Hepatitis E must be considered in the differential diagnosis of elevated hepatic enzyme levels and of systemic and neurological conditions of uncertain origin. The infection is usually self-limiting but can take a severe course in immunosuppressed persons. In such cases, ribavirin can be used as an antiviral treatment.
BACKGROUND: At least 17% of the population in Germany has been infected with the hepatitis E virus (HEV); thus, HEV infections are more frequent than was previously assumed. However, fewer than 500 HEV infections were reported to the Robert Koch Institute in 2013. METHOD: Review of pertinent literature retrieved by a selective search in PubMed. RESULTS:Persons living in Germany generally acquire hepatitis E infection within the country by consuming infected and undercooked pork; in rare cases, hepatitis E infections are imported from the tropics. HEV can be transmitted via blood products, blood transfusions, and organ transplantation. More than 99% of HEV infections are asymptomatic and self-limiting, but there are also severe cases with acute liver failure. Immunosuppressed persons can develop chronic HEV infection, potentially leading, within a few years, to liver cirrhosis with life-threatening sequelae. Moreover, HEV infection may be associated with extrahepatic manifestations such as Guillain-Barré syndrome. In two retrospectively evaluated case series, ribavirin was found to be active against HEV and can be used to treat either acute or chronic HEV infection. CONCLUSION:Hepatitis E must be considered in the differential diagnosis of elevated hepatic enzyme levels and of systemic and neurological conditions of uncertain origin. The infection is usually self-limiting but can take a severe course in immunosuppressed persons. In such cases, ribavirin can be used as an antiviral treatment.
Authors: Xinying Zhou; Yijin Wang; Herold J Metselaar; Harry L A Janssen; Maikel P Peppelenbosch; Qiuwei Pan Journal: J Hepatol Date: 2014-05-22 Impact factor: 25.083
Authors: Jeroen J J van Eijk; Richie G Madden; Annemiek A van der Eijk; Jeremy G Hunter; Johan H J Reimerink; Richard P Bendall; Suzan D Pas; Vic Ellis; Nens van Alfen; Laura Beynon; Lucy Southwell; Brendan McLean; Bart C Jacobs; Baziel G M van Engelen; Harry R Dalton Journal: Neurology Date: 2014-01-08 Impact factor: 9.910
Authors: S Pischke; P Stiefel; B Franz; B Bremer; P V Suneetha; A Heim; T Ganzenmueller; J Schlue; R Horn-Wichmann; R Raupach; M Darnedde; Y Scheibner; R Taubert; A Haverich; M P Manns; H Wedemeyer; C L Bara Journal: Am J Transplant Date: 2012-07-23 Impact factor: 8.086
Authors: P le Coutre; H Meisel; J Hofmann; C Röcken; G L Vuong; S Neuburger; P G Hemmati; B Dörken; R Arnold Journal: Gut Date: 2009-05 Impact factor: 23.059
Authors: Elizabeth B Haagsma; Hubert G M Niesters; Arie P van den Berg; Annelies Riezebos-Brilman; Robert J Porte; Harry Vennema; Johan H J Reimerink; Marion P G Koopmans Journal: Liver Transpl Date: 2009-10 Impact factor: 5.799
Authors: Mirko S Faber; Jürgen J Wenzel; Wolfgang Jilg; Michael Thamm; Michael Höhle; Klaus Stark Journal: Emerg Infect Dis Date: 2012-10 Impact factor: 6.883
Authors: Mark H Kuniholm; Edgar Ong; Boris M Hogema; Marco Koppelman; Kathryn Anastos; Marion G Peters; Eric C Seaberg; Yue Chen; Kenrad E Nelson; Jeffrey M Linnen Journal: Hepatology Date: 2016-01-16 Impact factor: 17.425